1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Arovella Therapeutics Limited
  6. News
  7. Summary
    ALA   AU0000182784

AROVELLA THERAPEUTICS LIMITED

(ALA)
  Report
Delayed Australian Stock Exchange  -  02:10 2022-08-17 am EDT
0.0250 AUD   -3.85%
07/28AROVELLA THERAPEUTICS : Quarterly Appendix 4C and Activities Report
PU
06/30Arovella Therapeutics Ltd Appoints Gary Phillips as an Independent Non-Executive Director
CI
06/27Arovella Therapeutics Limited Provides Sumatriptan Update
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SUDA Pharmaceuticals : Down 7% as Mitsubishi Tanabe Pharma Singapore Backs Out of ZolpiMist Supply Deal

01/25/2021 | 03:45am EDT


© MT Newswires 2021
All news about AROVELLA THERAPEUTICS LIMITED
07/28AROVELLA THERAPEUTICS : Quarterly Appendix 4C and Activities Report
PU
06/30Arovella Therapeutics Ltd Appoints Gary Phillips as an Independent Non-Executive Direct..
CI
06/27Arovella Therapeutics Limited Provides Sumatriptan Update
CI
06/21Arovella Therapeutics Partner STADA Begins Commercial Launch of Insomnia Drug in Austra..
MT
06/21Arovella Therapeutics Limited Announces ZolpiMist Launch Australia
CI
06/09Arovella Therapeutics Adopts WEF Framework for ESG Reporting
MT
06/07AROVELLA THERAPEUTICS : Adopts WEF Framework For ESG Reporting
PU
06/06Arovella Therapeutics Ltd Announces Executive Changes
CI
04/19Arovella Therapeutics Limited Signs Services Agreement with Qimr Berghofer Medical Rese..
CI
04/05Arovella Therapeutics Ltd Announces That the US Patent and Trademark Office Has Accepte..
CI
More news
Financials
Sales 2022 1,34 M 0,92 M 0,92 M
Net income 2022 -7,83 M -5,42 M -5,42 M
Net cash 2022 5,90 M 4,08 M 4,08 M
P/E ratio 2022 -2,50x
Yield 2022 -
Capitalization 16,7 M 11,6 M 11,6 M
EV / Sales 2022 8,13x
EV / Sales 2023 6,98x
Nbr of Employees 27
Free-Float 77,4%
Chart AROVELLA THERAPEUTICS LIMITED
Duration : Period :
Arovella Therapeutics Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AROVELLA THERAPEUTICS LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,03 AUD
Average target price 0,09 AUD
Spread / Average Target 260%
EPS Revisions
Managers and Directors
Michael Baker CEO, MD, Director & Chief Business Officer
Elizabeth Stoner Chairman
Debora Barton Independent Non-Executive Director
Gary Jonathan Phillips Independent Non-Executive Director
David Simmonds Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
AROVELLA THERAPEUTICS LIMITED-33.33%12
MODERNA, INC.-33.87%65 706
IQVIA HOLDINGS INC.-13.27%45 640
LONZA GROUP AG-26.68%43 587
SEAGEN INC.10.30%31 450
ALNYLAM PHARMACEUTICALS, INC.34.54%27 384